在一名对聚乙二醇干扰素-α/利巴韦林治疗无反应的慢性感染患者中鉴定出一种缺乏高变区1的丙型肝炎病毒突变体。 - Suppr

Identification of a hepatitis C virus mutant lacking the hypervariable region 1 in a chronically infected patient non-responding to PEG-interferon-alpha/ribavirin therapy.

作者信息

Kmieciak D, Migdalski P, Juszczyk J, Jagodziński P P, Trzeciak W H

机构信息

Department of Biochemistry and Molecular Biology, Karol Marcinkowski University of Medical Sciences, 6 Swiecickiego St., 60-781, Poznań, Poland.

出版信息

Eur J Clin Microbiol Infect Dis. 2009 Feb;28(2):211-3. doi: 10.1007/s10096-008-0608-1. Epub 2008 Aug 28.

DOI:10.1007/s10096-008-0608-1

PMID:18752008

Abstract

摘要

相似文献

Identification of a hepatitis C virus mutant lacking the hypervariable region 1 in a chronically infected patient non-responding to PEG-interferon-alpha/ribavirin therapy.在一名对聚乙二醇干扰素-α/利巴韦林治疗无反应的慢性感染患者中鉴定出一种缺乏高变区1的丙型肝炎病毒突变体。

Eur J Clin Microbiol Infect Dis. 2009 Feb;28(2):211-3. doi: 10.1007/s10096-008-0608-1. Epub 2008 Aug 28.

Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b.评估 1b 型丙型肝炎病毒患者对干扰素/利巴韦林联合治疗反应的病毒蛋白序列。

Protein J. 2012 Feb;31(2):129-36. doi: 10.1007/s10930-011-9381-6.

Summaries for patients. Re-treating patients with chronic hepatitis C who have not responded to peginterferon-alpha2b.患者摘要。对聚乙二醇化干扰素α-2b治疗无反应的慢性丙型肝炎患者进行再治疗。

Ann Intern Med. 2009 Apr 21;150(8):I-34. doi: 10.7326/0003-4819-150-8-200904210-00003.

Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.丙型肝炎高变区1：非裔美国人选择压力降低与治疗失败的关联

Dig Dis Sci. 2007 Oct;52(10):2540-9. doi: 10.1007/s10620-006-9726-8. Epub 2007 Apr 5.

Hepatitis C virus: five-year follow-up of patients with sustained virological response.

Rev Esp Enferm Dig. 2011 Feb;103(2):53-5. doi: 10.4321/s1130-01082011000200001.

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.聚乙二醇干扰素 α-2b/利巴韦林联合治疗时，用干扰素-β/利巴韦林进行导入治疗可能会改变 IL28B 微基因型慢性丙型肝炎患者的早期丙型肝炎病毒动力学。

J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

[Therapy of chronic Hepatitis C in 2008].[2008年慢性丙型肝炎的治疗]

MMW Fortschr Med. 2008 Mar 27;150(13):31-4. doi: 10.1007/BF03365407.

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.

Hepatology. 2009 Jun;49(6):2125; author reply 2125-6. doi: 10.1002/hep.22826.

[Is 24 weeks of peginterferon and ribavirin combination therapy sufficient for the patients with genotype 1 chronic hepatitis C?].[聚乙二醇干扰素和利巴韦林联合治疗24周对基因1型慢性丙型肝炎患者是否足够？]

Korean J Gastroenterol. 2010 Jul;56(1):59-61. doi: 10.4166/kjg.2010.56.1.59.

Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.丙型肝炎病毒 NS3 氨基末端区的二级结构与聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎的病毒学应答。

J Med Virol. 2010 Aug;82(8):1364-70. doi: 10.1002/jmv.21818.

引用本文的文献

Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy.对聚乙二醇干扰素α/利巴韦林（PEG-IFNα/RBV）治疗耐药的丙型肝炎病毒（HCV）感染患者中高变区1（HVR1）和蛋白激酶R结合结构域（PKR-BD）区域突变的鉴定。

J Appl Genet. 2015 Aug;56(3):403-9. doi: 10.1007/s13353-014-0267-0. Epub 2015 Jan 15.

Application of a high-resolution melting technique for the rapid detection of partial replacement of HCV-1b by HCV-1a after PEG-IFNα/RBV therapy.应用高分辨率熔解技术快速检测聚乙二醇干扰素α/利巴韦林治疗后丙型肝炎病毒1b型被丙型肝炎病毒1a型部分替代的情况。

J Appl Genet. 2015 May;56(2):271-5. doi: 10.1007/s13353-014-0256-3. Epub 2014 Nov 8.

本文引用的文献

Characterization of hepatitis C virus deletion mutants circulating in chronically infected patients.慢性感染患者中循环的丙型肝炎病毒缺失突变体的特征分析。

J Virol. 2007 Nov;81(22):12496-503. doi: 10.1128/JVI.01059-07. Epub 2007 Aug 29.

Contribution of insertions and deletions to the variability of hepatitis C virus populations.插入和缺失对丙型肝炎病毒群体变异性的作用。

J Gen Virol. 2007 Aug;88(Pt 8):2198-2203. doi: 10.1099/vir.0.82855-0.

Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls.对冷球蛋白血症患者及相关对照的丙型肝炎病毒高变区1序列分析。

J Virol. 2007 May;81(9):4564-71. doi: 10.1128/JVI.02104-06. Epub 2007 Feb 21.

Mutations within protein kinase R-binding domain of NS5A protein of hepatitis C virus (HCV) and specificity of HCV antibodies in pretreatment sera of HCV-chronically infected patients and their effect on the result of treatment.丙型肝炎病毒（HCV）NS5A蛋白的蛋白激酶R结合域内的突变、HCV慢性感染患者治疗前血清中HCV抗体的特异性及其对治疗结果的影响。

Jpn J Infect Dis. 2006 Apr;59(2):92-9.

A correlation between the heterogeneity of hypervariable region 1 of E2 glycoprotein of Hepatitis C virus (HCV) and HCV antibody profile: a case study.丙型肝炎病毒（HCV）E2糖蛋白高变区1的异质性与HCV抗体谱的相关性：一项病例研究。

Acta Virol. 2005;49(2):97-103.

Predictors of response to therapy for chronic hepatitis C.慢性丙型肝炎治疗反应的预测因素。

Semin Liver Dis. 2004;24 Suppl 2:25-31. doi: 10.1055/s-2004-832925.

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes.含有功能性E1-E2包膜蛋白复合物的传染性丙型肝炎病毒假颗粒。

J Exp Med. 2003 Mar 3;197(5):633-42. doi: 10.1084/jem.20021756.

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.人类B类I型清道夫受体是丙型肝炎病毒的一种新型候选受体。

EMBO J. 2002 Oct 1;21(19):5017-25. doi: 10.1093/emboj/cdf529.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎病毒感染

N Engl J Med. 2002 Sep 26;347(13):975-82. doi: 10.1056/NEJMoa020047.

A 385 insertion in the hypervariable region 1 of hepatitis C virus E2 envelope protein is found in some patients with mixed cryoglobulinemia type 2.在一些Ⅱ型混合性冷球蛋白血症患者中发现丙型肝炎病毒E2包膜蛋白高变区1存在385个碱基的插入。

Blood. 2001 Nov 1;98(9):2657-63. doi: 10.1182/blood.v98.9.2657.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Identification of a hepatitis C virus mutant lacking the hypervariable region 1 in a chronically infected patient non-responding to PEG-interferon-alpha/ribavirin therapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献